Relación entre el valor del antígeno prostático específico al momento de iniciar radioterapia de salvamento posterior a prostatectomía radical y la progresión a recaída bioquímica en pacientes con cáncer de próstata

Vista sencilla de ítem
dc.contributor.advisorVillareal Trujillo, Nicolás
dc.contributor.advisorCamacho López, Paul Anthony
dc.contributor.apolounabCamacho López, Paul Anthony [paul-anthony-camacho-lópez]
dc.contributor.authorMantilla Rey, Daniel José
dc.contributor.cvlacVillareal Trujillo, Nicolás [0001691724]spa
dc.contributor.cvlacCamacho López, Paul Anthony [0000323578]spa
dc.contributor.googlescholarMantilla Rey, Daniel José [D6tAXGsAAAAJ&hl=es&oi=sra]spa
dc.contributor.googlescholarCamacho López, Paul Anthony [-u8d7_QAAAAJ]spa
dc.contributor.linkedinCamacho López, Paul Anthony [paulcamachomdepi]
dc.contributor.orcidCamacho López, Paul Anthony [0000-0002-6233-9582]spa
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2019spa
dc.date.accessioned2022-08-01T19:37:24Z
dc.date.available2022-08-01T19:37:24Z
dc.date.issued2019
dc.degree.nameEspecialista en Urologíaspa
dc.description.abstractEl cáncer de próstata es una de las patologías oncológicas con mayor incidencia y prevalencia a nivel mundial. Dentro de las opciones terapéuticas, la prostatectomía radical ha logrado aumentar la supervivencia global y cáncer específica, así como disminuir la mortalidad global en los pacientes con cáncer de próstata localizado. A pesar de los buenos resultados oncológicos logrados con este procedimiento, múltiples estudios han mostrado diversas tasas de progresión bioquímica de la enfermedad las cuales pueden variar desde un 15 a 60%. La radioterapia de salvamento posterior a la prostatectomía radical es la opción de tratamiento mas frecuentemente utilizada, con el fin de controlar la enfermedad, sin embargo aún no esta claro el verdadero alcance, y las características optimas del paciente y la enfermedad para maximizar sus resultados, lo que requiere realizar más estudios. Basados en esto se hace necesario realizar un estudio para evaluar el uso de esta técnica en nuestra institución y poder evaluar los resultados obtenidos en nuestra población.spa
dc.description.abstractenglishProstate cancer is one of the oncological pathologies with the highest incidence and prevalence worldwide. Among the therapeutic options, radical prostatectomy has managed to increase overall and cancer-specific survival, as well as reduce overall mortality in patients with localized prostate cancer. Despite the good oncological results achieved with this procedure, multiple studies have shown various rates of biochemical progression of the disease, which can vary from 15 to 60%. Salvage radiotherapy after radical prostatectomy is the most frequently used treatment option, in order to control the disease, however the true scope, and the optimal characteristics of the patient and the disease to maximize its results, are still unclear. which requires further studies. Based on this, it is necessary to carry out a study to evaluate the use of this technique in our institution and to be able to evaluate the results obtained in our population.spa
dc.description.degreelevelEspecializaciónspa
dc.description.learningmodalityModalidad Presencialspa
dc.description.tableofcontentsRESUMEN PLANTEAMIENTO DEL PROBLEMA DE INVESTIGACIÓN Y JUSTIFICACIÓN MARCO TEÓRICO ESTADO DEL ARTE OBJETIVOS METODOLOGÍA PROCEDIMIENTO CONTROL DE CALIDAD CONSIDERACIONES ÉTICAS RESULTADOS DISCUSIÓN CONCLUSIÓN BIBLIOGRAFÍA Anexo No. 1 – VARIABLES ANEXO NO. 2 – CRFspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/17173
dc.language.isospaspa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.publisher.programEspecialización en Urologíaspa
dc.relation.references[1] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.spa
dc.relation.references[2] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.spa
dc.relation.references3] Li C, Ekwueme DU. Years of potential life lost caused by prostate cancer deaths in the United States-Projection from 2004 through 2050. Cancer Epidemiol. 2010;34(4):368-72.spa
dc.relation.references[4] Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Bogotá: Instituto Nacional de Cancerología. 2015.spa
dc.relation.references[5] Claudia U, Sonia O, Herrera V. Incidencia y mortalidad por cáncer en el área metropolitana de Bucaramanga 2003-2007. Colombia Médica. 2012;43(4):290-7spa
dc.relation.references[6] Bill-axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-42.spa
dc.relation.references[7] Meltzer D, Egleston B, Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health. 2001;91(1):126-8.spa
dc.relation.references[8] Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910-4.spa
dc.relation.references[9] Kane CJ, Im R, Amling CL, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3):695-700.spa
dc.relation.references[10] Pound CR, Partin AW, Eisenberger MA, et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. JAMA Otolaryngol Head Neck Surg. 2015;141(5):428.spa
dc.relation.references[11] Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171(4):1393-401.spa
dc.relation.references[12] Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163(6):1632-42.spa
dc.relation.references[13] Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59(6):893-9.spa
dc.relation.references14] Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035-41.spa
dc.relation.references[15] Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65(6):1034-43.spa
dc.relation.references[16] Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy - what is the best time to treat?. Radiother Oncol. 2012;103(2):239-43.spa
dc.relation.references[17] Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer. 2012;48(6):837-44.spa
dc.relation.references[18] Stephenson AJ, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein E a, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. 2012;291(11):1325–32.spa
dc.relation.references[19] Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–54.spa
dc.relation.references[20] King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104-11.spa
dc.relation.references[21] Taguchi S, Shiraishi K, Fukuhara H, et al. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?. Radiat Oncol. 2016;11:102.spa
dc.relation.references[22] Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760-9.spa
dc.relation.references[23] Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol [Internet]. 2016;69(4):728–33.spa
dc.relation.references[24] Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, et al. Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring System. J Urol. 2006;176(3):985–90.spa
dc.relation.references25] Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28.spa
dc.relation.references[26] Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–56.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsUrologyspa
dc.subject.keywordsMedicinespa
dc.subject.keywordsProstate cancerspa
dc.subject.keywordsRadiotherapyspa
dc.subject.keywordsBiochemistryspa
dc.subject.keywordsProstate diseasesspa
dc.subject.keywordsNeoplasms of the male genital tractspa
dc.subject.keywordsRadiotherapyspa
dc.subject.lembUrologíaspa
dc.subject.lembMedicinaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembEnfermedades de la próstataspa
dc.subject.lembNeoplasmas del aparato genital masculinospa
dc.subject.lembRadioterapiaspa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalCáncer de próstataspa
dc.subject.proposalRadioterapiaspa
dc.subject.proposalBioquímicaspa
dc.titleRelación entre el valor del antígeno prostático específico al momento de iniciar radioterapia de salvamento posterior a prostatectomía radical y la progresión a recaída bioquímica en pacientes con cáncer de próstataspa
dc.title.translatedRelationship between the value of prostate-specific antigen at the time of starting salvage radiotherapy after radical prostatectomy and progression to biochemical relapse in patients with prostate cancerspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM

Archivos

Bloque original

Mostrando 1 - 3 de 3
Miniatura
Nombre:
2019_Tesis_Mantilla_Daniel.pdf
Tamaño:
857.96 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis
Descargar
Miniatura
Nombre:
2019_Presentación_Mantilla_Daniel.pdf
Tamaño:
541.46 KB
Formato:
Adobe Portable Document Format
Descripción:
Presentación
Descargar
Miniatura
Nombre:
Licencia_Daniel.pdf
Tamaño:
315.44 KB
Formato:
Adobe Portable Document Format
Descripción:
Licencia
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
829 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Urología